-
In this study, 249 mice who were identified with SCC tumors received treatment with a range of drug regimens.
-
Over the course of 45 days, tumor development was observed and measured.
-
The purpose of this study was to compare the performance of Pymaceuticals’ drug of interest, Capomulin, against the other treatment regimens.
-
Figures needed for the technical report of the clinical study were genereted using Pandas and matplotlib.
-
The drug produced by the pharma company Capomulin works better in reduction of the tumor volume as interpreted from the statistics summary(mean) in comparison to most drugs from other companies. Another drug Ramicane has similar results as Capomulin over the time when measurements were taken.
-
The number of measurements for Capomulin and Ramicane are also higher than those taken for other drugs(aleast 60 more measurements were taken for these two) as analysed by the bar graph.
-
Male mice involved in the study were two percent more than those of female mice as interpreted fro the pie graph.
-
The final tumor volumes have less variation in volume for Capomulin and Ramicane in comparison to Infubinol and Ceftamin as shown by the box plot.
-
Final tumor volume data for the capomulin is skewed as interpreted by the median line on the box plot.
-
The line plot for the tumor volume vs timepoint shows that Capomulin does have impact in reduction of the tumor volume over the period of time for different mice.
-
There is a strong correlation between the tumor volume and weight of the mice as given by the correlation value(0.84).
